MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 127182 | Name: Clamikalant monosodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clamikalant inhibits ATP-sensitive potassium channel.

Chemical Structure

Clamikalant monosodium
Clamikalant monosodium
CAS#261717-22-0 (sodium)

Theoretical Analysis

MedKoo Cat#: 127182

Name: Clamikalant monosodium

CAS#: 261717-22-0 (sodium)

Chemical Formula: C19H21ClN3NaO5S2

Exact Mass: 493.0509

Molecular Weight: 493.95

Elemental Analysis: C, 46.20; H, 4.29; Cl, 7.18; N, 8.51; Na, 4.65; O, 16.19; S, 12.98

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
25mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
158751-64-5 (free base) 261717-22-0 (sodium)
Synonym
Clamikalant monosodium; HMR-1098; HMR1098; HMR 1098
IUPAC/Chemical Name
sodium ((5-(2-(5-chloro-2-methoxybenzamido)ethyl)-2-methoxyphenyl)sulfonyl)(methylcarbamothioyl)amide
InChi Key
SUEVHDKFEXAKAF-UHFFFAOYSA-M
InChi Code
InChI=1S/C19H22ClN3O5S2.Na/c1-21-19(29)23-30(25,26)17-10-12(4-6-16(17)28-3)8-9-22-18(24)14-11-13(20)5-7-15(14)27-2;/h4-7,10-11H,8-9H2,1-3H3,(H3,21,22,23,24,29);/q;+1/p-1
SMILES Code
CNC([N-]S(=O)(C1=CC(CCNC(C2=C(C=CC(Cl)=C2)OC)=O)=CC=C1OC)=O)=S.[Na+]
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 493.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: O'Rourke ST. Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7. PMID: 16047257. 2: Gross GJ. The role of mitochondrial KATP channels in cardioprotection. Basic Res Cardiol. 2000 Aug;95(4):280-4. doi: 10.1007/s003950050004. PMID: 11005582. 3: Gögelein H, Hartung J, Englert HC. Molecular basis, pharmacology and physiological role of cardiac K(ATP) channels. Cell Physiol Biochem. 1999;9(4-5):227-41. doi: 10.1159/000016319. PMID: 10575200. 4: Billman GE. A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti- arrhythmic drug development. Pharmacol Ther. 2006 Sep;111(3):808-35. doi: 10.1016/j.pharmthera.2006.01.002. Epub 2006 Feb 17. PMID: 16483666. 5: Zehender M, Faber T, Brunner M, Grom A. Akute Myokardischämie und ventrikuläre Arrhythmien in der Pathogenese des plötzlichen Herztodes bei koronarer Herzkrankheit [Acute myocardial ischemia and ventricular arrhythmias in the pathogenesis of sudden cardiac death in coronary disease]. Z Kardiol. 2000;89 Suppl 3:13-23. German. PMID: 10810781. 6: Kim MY, Lee S, Yi KY, Yoo SE, Lee DH, Lim H, Kim HS, Lee SH, Baik EJ, Moon CH, Jung YS. Protective effect of KR-31378 on oxidative stress in cardiac myocytes. Arch Pharm Res. 2005 Dec;28(12):1358-64. doi: 10.1007/BF02977902. PMID: 16392669. 7: Englert HC, Gerlach U, Goegelein H, Hartung J, Heitsch H, Mania D, Scheidler S. Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98. doi: 10.1021/jm000985v. PMID: 11297455. 8: Birincioglu M, Yang XM, Critz SD, Cohen MV, Downey JM. S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning. Am J Physiol. 1999 Dec;277(6):H2435-41. doi: 10.1152/ajpheart.1999.277.6.H2435. PMID: 10600866. 9: Rodrigo GC, Davies NW, Standen NB. Diazoxide causes early activation of cardiac sarcolemmal KATP channels during metabolic inhibition by an indirect mechanism. Cardiovasc Res. 2004 Feb 15;61(3):570-9. doi: 10.1016/j.cardiores.2003.10.004. PMID: 14962487. 10: Vajda S, Baczkó I, Leprán I. Selective cardiac plasma-membrane K(ATP) channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion. Eur J Pharmacol. 2007 Dec 22;577(1-3):115-23. doi: 10.1016/j.ejphar.2007.08.016. Epub 2007 Aug 19. PMID: 17904545. 11: Krismer AC, Wenzel V, Voelckel W, Witkiewicz M, Strohmenger HU, Raedler C, Lindner KH. Effect of the cardioselective ATP-sensitive potassium channel inhibitor HMR 1883 in a porcine model of cardiopulmonary resuscitation. Resuscitation. 2002 Jun;53(3):299-306. doi: 10.1016/s0300-9572(02)00038-2. PMID: 12062846. 12: Russ U, Lange U, Löffler-Walz C, Hambrock A, Quast U. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP- sensitive K(+) channels: comparison with glibenclamide. J Pharmacol Exp Ther. 2001 Dec;299(3):1049-55. PMID: 11714894. 13: Wirth KJ, Rosenstein B, Uhde J, Englert HC, Busch AE, Schölkens BA. ATP- sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia- associated electrocardiographic changes in pigs with coronary occlusion. J Pharmacol Exp Ther. 1999 Nov;291(2):474-81. PMID: 10525061. 14: Moon CH, Kim MY, Kim MJ, Kim MH, Lee S, Yi KY, Yoo SE, Lee DH, Lim H, Kim HS, Lee SH, Baik EJ, Jung YS. KR-31378, a novel benzopyran analog, attenuates hypoxia-induced cell death via mitochondrial KATP channel and protein kinase C-epsilon in heart-derived H9c2 cells. Eur J Pharmacol. 2004 Dec 3;506(1):27-35. doi: 10.1016/j.ejphar.2004.10.037. PMID: 15588621. 15: Das B, Sarkar C. Cardiomyocyte mitochondrial KATP channels participate in the antiarrhythmic and antiinfarct effects of KATP activators during ischemia and reperfusion in an intact anesthetized rabbit model. Pol J Pharmacol. 2003 Sep-Oct;55(5):771-86. PMID: 14704474. 16: Das B, Sarkar C. Mitochondrial K ATP channel activation is important in the antiarrhythmic and cardioprotective effects of non-hypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model. Pharmacol Res. 2003 Jun;47(6):447-61. doi: 10.1016/s1043-6618(02)00335-3. PMID: 12741997. 17: Jung O, Englert HC, Jung W, Gögelein H, Schölkens BA, Busch AE, Linz W. The K(ATP) channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):445-51. doi: 10.1007/s002109900212. PMID: 10763861. 18: Das B, Sarkar C. Selective mitochondrial KATP channel activation by nicorandil and 3-pyridyl pinacidil results in antiarrhythmic effect in an anesthetized rabbit model of myocardial ischemia/reperfusion. Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):97-110. doi: 10.1358/mf.2003.25.2.723683. PMID: 12731455. 19: Toyoda Y, Friehs I, Parker RA, Levitsky S, McCully JD. Differential role of sarcolemmal and mitochondrial K(ATP) channels in adenosine-enhanced ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2694-703. doi: 10.1152/ajpheart.2000.279.6.H2694. PMID: 11087223. 20: Kilbinger H, Krause A, Mang CF, Englert H, Wirth K. Effects of K(ATP) channel modulators on acetylcholine release from guinea-pig isolated atria and small intestine. Naunyn Schmiedebergs Arch Pharmacol. 2002 May;365(5):371-7. doi: 10.1007/s00210-002-0539-9. Epub 2002 Mar 19. PMID: 12012023.